Shares of BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) have earned an average rating of “Moderate Buy” from the nine brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $286.43.
BGNE has been the subject of several research analyst reports. Morgan Stanley increased their price objective on shares of BeiGene from $295.00 to $325.00 and gave the company an “overweight” rating in a research report on Tuesday. Cowen raised their price target on shares of BeiGene from $200.00 to $213.00 in a research report on Thursday, November 10th. Daiwa Capital Markets began coverage on shares of BeiGene in a research report on Wednesday, January 11th. They set a “buy” rating and a $308.00 price target for the company. Guggenheim raised their price target on shares of BeiGene from $290.00 to $350.00 and gave the stock a “buy” rating in a research report on Friday, January 20th. Finally, SVB Leerink lifted their target price on shares of BeiGene from $236.00 to $300.00 and gave the company an “outperform” rating in a report on Friday, January 20th.
Insider Transactions at BeiGene
In related news, insider Xiaodong Wang sold 2,500 shares of the business’s stock in a transaction dated Wednesday, January 11th. The shares were sold at an average price of $252.66, for a total value of $631,650.00. Following the sale, the insider now directly owns 5,512,556 shares in the company, valued at approximately $1,392,802,398.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO John Oyler sold 25,000 shares of the business’s stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $206.84, for a total value of $5,171,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Xiaodong Wang sold 2,500 shares of the business’s stock in a transaction dated Wednesday, January 11th. The shares were sold at an average price of $252.66, for a total transaction of $631,650.00. Following the completion of the sale, the insider now owns 5,512,556 shares in the company, valued at $1,392,802,398.96. The disclosure for this sale can be found here. Insiders have sold a total of 43,033 shares of company stock worth $9,407,504 in the last quarter. Company insiders own 7.50% of the company’s stock.
Institutional Trading of BeiGene
BeiGene Trading Down 0.8 %
NASDAQ BGNE opened at $266.75 on Wednesday. The company’s 50-day moving average price is $220.10 and its 200-day moving average price is $186.90. The company has a current ratio of 4.07, a quick ratio of 3.87 and a debt-to-equity ratio of 0.04. The stock has a market cap of $27.73 billion, a PE ratio of -12.49 and a beta of 0.78. BeiGene has a 12 month low of $118.18 and a 12 month high of $280.62.
BeiGene (NASDAQ:BGNE – Get Rating) last issued its earnings results on Wednesday, November 9th. The company reported ($5.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.02) by ($1.37). BeiGene had a negative return on equity of 38.92% and a negative net margin of 171.94%. The business had revenue of $387.63 million for the quarter, compared to the consensus estimate of $360.25 million. Equities research analysts forecast that BeiGene will post -18.27 earnings per share for the current year.
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).
- Get a free copy of the StockNews.com research report on BeiGene (BGNE)
- Can Coty Stock Emerge in 2023 With Upside
- Should You Bet Against The Nasdaq 100 With This Inverse ETF?
- Insiders Buy Archer Aviation, Is This Stock About To Take Off?
- Intuit Is About To Make a Move, But Which Way?
- 3 Late January Earnings Plays With Pop Potential
Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.